Douglas Forsyth, Director at Inhibrx Biosciences, Inc. (INBX), bought 150,000 shares at $12.89 ($2.1M) on 2024-08-22, disclosed to the SEC on 2024-08-26.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.89 | 15,188 | $196K | 9.4% |
| 2 | $12.89 | 15,188 | $196K | 9.4% |
| 3 | $14.07 | 59,812 | $842K | 40.6% |
| 4 | $14.07 | 59,812 | $842K | 40.6% |
| Total | $13.83 avg | 150,000 | $2.1M | 100% |
| Filing → |
| NCV | SELL | 2014-06-27 | $159K | — | Filing → |
| NIE | BUY | 2008-09-22 | $151K | — | Filing → |
| NIE | BUY | 2007-08-21 | $108K | — | Filing → |